Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M698Revenue $M17.2Net Margin (%)492Z-Score9.3
Enterprise Value $M593EPS $2.1Operating Margin %537F-Score7
P/E(ttm))10.5Cash Flow Per Share $-1.6Pre-tax Margin (%)502Higher ROA y-yY
Price/Book6.510-y EBITDA Growth Rate %0Quick Ratio7.6Cash flow > EarningsY
Price/Sales35.35-y EBITDA Growth Rate %0Current Ratio7.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)49.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)69.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M41.9ROI % (ttm)-221.3Gross Margin Increase y-yN

Gurus Latest Trades with ANAC

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ANACJean-Marie Eveillard 2013-03-31 Sold Out -0.0017%$3.15 - $6.52
($4.32)
$ 16.65285%Sold Out0
ANACJean-Marie Eveillard 2012-12-31 Buy $4.6 - $6.81
($5.55)
$ 16.65200%New holding, 92390 sh.92,390
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ANAC is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ANAC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Maples Kirk RSVP, Program Management 2014-06-04Sell1,620$14.713.27 view
Maples Kirk RSVP, Program Management 2014-05-20Sell1,500$14.1517.67 view
Maples Kirk RSVP, Program Management 2014-04-21Sell1,500$15.66.73 view
Parker Geoffrey M.Senior Vice President and CFO 2014-03-24Buy5,000$20.11-17.21 view
Shapiro LucyDirector 2014-03-21Sell80,000$21.14-21.24 view
Maples Kirk RSVP, Program Management 2014-03-20Sell3,000$22.39-25.64 view
Parker Geoffrey M.Senior Vice President and CFO 2014-03-18Buy2,410$22.6-26.33 view
PERRY DAVID PPresident and CEO 2014-03-05Sell65,000$20.22-17.66 view
Maples Kirk RSVP, Program Management 2014-02-20Sell3,000$19.33-13.86 view
PERRY DAVID PPresident and CEO 2014-02-05Sell15,000$17-2.06 view

Press Releases about ANAC :

Quarterly/Annual Reports about ANAC:

News about ANAC:

Articles On GuruFocus.com
3 Great Dividend Stocks at All-Time Highs Aug 19 2013 
Weekly CFO Buys Highlight Aug 19 2013 
Senior Vice President and CFO of Anacor Pharmaceuticals Inc. Geoffrey Parker Bought 43,046 Shares Jun 20 2013 
This Week's Top Insider Buys Jun 19 2013 
comment on ANAC Mar 15 2013 
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: GSVC, SHO, YAVY, CMCSA, ANAC May 16 2011 

More From Other Websites
Anacor's Kerydin to Be Commercialized by Sandoz in the U.S. Jul 22 2014
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% Jul 22 2014
Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in... Jul 21 2014
ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 21 2014
Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in... Jul 21 2014
Anacor's Kerydin Gets FDA Nod for Onychomycosis Jul 09 2014
ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 08 2014
FDA Approves Anacor Pharmaceuticals' KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment... Jul 08 2014
FDA Approves Anacor Pharmaceuticals’ KERYDIN™ (Tavaborole) Topical Solution, 5% for the... Jul 08 2014
5-Star Biotech Stock Watch: Anacor Pharmaceuticals Jul 02 2014
FDA Oks Valeant toenail fungus treatment Jublia Jun 09 2014
FDA Oks Valeant toenail fungus treatment Jublia Jun 09 2014
ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 02 2014
Anacor Pharmaceuticals Appoints Keith R. Leonard, Jr. to Board of Directors May 30 2014
Anacor Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference May 28 2014
ANACOR PHARMACEUTICALS, INC. Financials May 20 2014
Anacor Pharmaceuticals to Present at the UBS Global Health Care Conference May 13 2014
ANACOR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 12 2014
Anacor Reports Wider-than-Expected Q1 Loss May 09 2014
Anacor Pharmaceuticals Inc Stock Downgraded (ANAC) May 09 2014
Anacor Pharmaceuticals' (ANAC) CEO Paul Berns On Q1 2014 Results - Earnings Call Transcript May 07 2014
ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2014
Anacor Pharmaceuticals Reports First Quarter 2014 Financial Results May 07 2014
Anacor Pharmaceuticals Appoints Paul L. Berns as Chief Executive Officer Mar 19 2014
Anacor Pharmaceuticals Reports 2013 Fourth Quarter and Year-End Financial Results Mar 13 2014
Anacor Pharmaceuticals Announces Appointment of Vince Ippolito as Chief Commercial Officer Mar 10 2014
Anacor Pharmaceuticals Announces 2013 Fourth Quarter and Year End Financial Results Conference Call... Mar 06 2014
Anacor Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA for the... Feb 27 2014
Anacor Pharmaceuticals to Present at the Cowen & Company 34th Annual Health Care Conference Feb 26 2014
Anacor Pharmaceuticals Announces Publication of Article Describing Boron-Containing Compounds and... Feb 13 2014
Anacor Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference Nov 27 2013
Anacor Pharmaceuticals Announces Positive Preliminary Results from AN2728 MUSE Study in Pediatric... Nov 12 2013
Anacor Pharmaceuticals Reports Third Quarter 2013 Financial Results Nov 07 2013
Anacor Pharmaceuticals Announces Third Quarter 2013 Financial Results Conference Call and Webcast Nov 04 2013
Anacor Pharmaceuticals Announces Settlement Agreement with Valeant Pharmaceuticals Oct 28 2013

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide